Jefferies Raises Price Target On Regeneron Pharma (REGN) to $111

Jefferies boosted its price target on Regeneron Pharma (NASDAQ: REGN) from $75 to $111 and reiterated its Buy rating following in-line Bascom-Palmer data.

The firm comments, "2-yr VIEW data at Bascom-Palmer were generally in-line with our expectations with expert commentaries on Eylea’s outlook in AMD and also consistent with our assumptions and recent survey results anticipating meaningful Eylea mkt share gains. We are increasing our PT to $111 from $75 largely on increased DME sales ests driven by increased adoption."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $96.86 yesterday, with a 52 week range of $33.90-$97.56.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Barclays Cuts PT and Estimates on Dell (DELL); Apple's (AAPL) Momentum Proves Disrupting
• Barclays Maintains an 'Equalweight' on J. C. Penney (JCP); Slashing PT on Disappointing Results
• UBS Maintains a 'Buy' on Express Inc. (EXPR); A Misstep, But Still A Consistent Performer

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter